Department of Physiatry, Hospital for Special Surgery, New York, New York.
Department of Physical Medicine & Rehabilitation, Yale New Haven Hospital, New Haven, Connecticut.
Clin J Sport Med. 2022 Nov 1;32(6):558-566. doi: 10.1097/JSM.0000000000001029. Epub 2022 Mar 17.
To compare the efficacy of ultrasound-guided hyaluronic acid (HA) versus leukocyte-poor platelet-rich plasma (LP-PRP) injection in the treatment of glenohumeral osteoarthritis.
Double-blind randomized controlled trial.
Academic institution.
Seventy patients with chronic glenohumeral osteoarthritis were randomly assigned to receive a single injection of HA (n = 36) or LP-PRP (n = 34).
Leukocyte-poor platelet-rich plasma was processed using Harvest/TerumoBCT Clear PRP kits. Ultrasound-guided injections of 6 mL HA or 6 mL LP-PRP into the glenohumeral joint were performed. Patients, the injecting physician, and outcomes assessor were blinded to treatment assignments.
Shoulder Pain and Disability Index (SPADI), American Shoulder and Elbow Surgeons (ASES) score, current/average numerical rating scale (NRS) pain scores, satisfaction, and side effects were assessed at the 5 follow-up time points over 12 months.
Baseline characteristics were similar between groups. There were no significant between-group differences regarding SPADI, ASES, and current/average NRS pain scores at any time point up to 12 months postinjection ( P > 0.05). However, significant improvements in SPADI, ASES, and current/average NRS pain scores were observed in both groups starting at 1 or 2 months ( P < 0.01, P < 0.01, P < 0.001, and P < 0.01, respectively). These improvements were observed regardless of osteoarthritis severity. For patients who received LP-PRP, there was no effect of platelet yield on outcomes. Side effect and satisfaction rates were similar between groups.
There were no differences in pain and functional outcomes after a single injection of LP-PRP versus HA. However, significant improvements in pain and function were observed after both treatments in patients with glenohumeral osteoarthritis.
比较超声引导下透明质酸(HA)与富含白细胞血小板的血浆(LP-PRP)注射治疗肩袖撞击综合征的疗效。
双盲随机对照试验。
学术机构。
70 例慢性肩袖撞击综合征患者被随机分为 HA 组(n = 36)或 LP-PRP 组(n = 34),每组接受单次关节内注射。
采用 Harvest/TerumoBCT Clear PRP 试剂盒处理富含白细胞的血小板。对肩袖撞击综合征患者进行超声引导下关节内注射 6 mL HA 或 6 mL LP-PRP。患者、注射医生和结果评估者对治疗分配均设盲。
肩关节疼痛和残疾指数(SPADI)、美国肩肘外科医师协会(ASES)评分、当前/平均数字评分量表(NRS)疼痛评分、满意度和副作用,在 12 个月的 5 次随访时间点进行评估。
两组患者的基线特征相似。在注射后 12 个月内的任何时间点,两组间 SPADI、ASES 和当前/平均 NRS 疼痛评分均无显著差异(P > 0.05)。然而,两组患者在注射后 1 或 2 个月时 SPADI、ASES 和当前/平均 NRS 疼痛评分均显著改善(P < 0.01,P < 0.01,P < 0.001 和 P < 0.01,分别)。无论骨关节炎严重程度如何,均观察到这些改善。对于接受 LP-PRP 治疗的患者,血小板产量对结局无影响。两组患者的副作用和满意度发生率相似。
单次注射 LP-PRP 与 HA 治疗肩袖撞击综合征后疼痛和功能结局无差异。然而,两种治疗方法均能显著改善肩袖撞击综合征患者的疼痛和功能。